TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion diagnosed with a psychotic disorder
Endpoint domain: Mortality/survival
Primary endpoint: composite primary clinical end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of redirections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior wall penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: melatonin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: intra-operative anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2000 m ergometer time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Phase coupling in RR, SBP, and between RR‐SBP and RR‐VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phase coupling between CBFM‐PETCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of epigastric pain
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients healed by 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to healing
Endpoint domain: Mortality/survival
Primary endpoint: Complete response (CR) and partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median progression free interval
Endpoint domain: Mortality/survival
Primary endpoint: mean visual-acuity letter score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant acceptance of discontinuation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of renal scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean PLT loss per product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: amotosalen concentration after CAD treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difficulty with activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity of observers' ability to detect Acting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of observers' ability to detect Acting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral health problems prevention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: primary endpoint occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in average IGA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final average Merz grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in under-eye bags appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: joint damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of facial pore size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhagic rate
Endpoint domain: Adverse events/effects
Primary endpoint: Sinus rhythm at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AGE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein glycosylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in TOPSE scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in GERD-related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healthy BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-PCI myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint of death from any cause, post-PCI myocardial infarction, MI after PCI hospitalization or ischemia-driven target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to antinauseants for NVP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vein-graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death, myocardial infarction, or repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: reduction in recidivism risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reported less physical violence after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for assisted or controlled mask ventilation after extubation
Endpoint domain: Adverse events/effects
Primary endpoint: students' self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: freedom from angina at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: need for reintervention after 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression-free survival time (PFST)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of respiratory infections
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of needlestick injuries (NSI)
Endpoint domain: Adverse events/effects
Primary endpoint: improvement of symptoms in children with heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tolerance to nAAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast symptoms score (BRBS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hot-flash frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginalization index
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Delivery before 37 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Composite adverse perinatal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in spine compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in anterior‐posterior shear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in lateral shear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Infant growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall GLQI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: preserved baroreflex function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hemodynamic protection during laryngoscopy and tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour ILV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-week ILV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of low-volume PEG containing ascorbic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of low-volume PEG containing ascorbic acid
Endpoint domain: Adverse events/effects
Primary endpoint: mean overnight oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: vAMI risk
Endpoint domain: Mortality/survival
Primary endpoint: dAMI risk
Endpoint domain: Mortality/survival
Primary endpoint: Clinical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in SIgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in serum ALB and PALB concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in serum IgA and IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Purchase of CPR kit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative voiding dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first 24-h heartburn-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first daytime or nighttime heartburn-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of time patients were heartburn-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: limb salvage and wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal aspirate amikacin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tracheal aspirate fosfomycin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: degree of impairment associated with depression and comorbidity of disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 50% or greater reduction in migraines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at injection site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Histologic rejection grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ocular staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasomotor symptom interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year cause-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Trough FVC improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean distance walked during shuttle walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St. George's Respiratory Questionnaire total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastric myoelectric activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with ST segment depression greater than or equal to 1 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak heart rate during symptom-limited test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise duration during symptom-limited test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detectable hand nicotine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall agreement percentage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chance-adjusted agreement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Likelihood of poor outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NBNA scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in phobic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %LBW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gastrointestinal GvHD grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in reconstruction parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: truncal fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TDT threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FPT threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of calcium including soya-based foods, milk, and vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interest in trying steroids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Belief in steroid use as a good idea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of alternatives to steroid use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of hairs pulled out
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients developing PHN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ureteral colic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative fentanyl consumption for rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of demanded and delivered fentanyl boluses for rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque echogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GSM increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of echolucent plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cross-sectional area stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lumen loss prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EC50 of ropivacaine for postoperative epidural analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of service delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of the overall technical environment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical objectives reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time elapsed between inclusion and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Re-operations
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intrapartum complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: improved social quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: improved physical quality of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: amount of midazolam used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of the first exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of COPD exacerbations per patient year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cost per month per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Event free survival rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Serum ALP reduction of more than 25% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with serum ALP levels declined more than 40%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with pruritus/scratch
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of second cancers
Endpoint domain: Mortality/survival
Primary endpoint: mean biting force (mBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean bone level (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total glutathione concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new-onset atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of sinus tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma IL-6 level at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: instillation pain
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ventricular response (VR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of bipolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sucrase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraepithelial lymphocytes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: tooth development speed of MXC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak countermovement jump power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: leg press one-repetition maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of heavy episodic drinking occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for IV supplemental drugs for pain relief
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: new dfs (decayed and filled surfaces)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintained abstinence
Endpoint domain: Mortality/survival
Primary endpoint: number of daily walking breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to prompts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes per day spent in walking breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of attention during anaesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of erlotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Steady-state trough plasma concentrations of erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with prescribed dose of charcoal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of pimodivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC12h of pimodivir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhoea (adverse event)
Endpoint domain: Adverse events/effects
Primary endpoint: dose or duration of sedatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: management of stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: management of cognitive problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evidence of periapical healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in root length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes